HeartBeam Inc. (NASDAQ: BEAT) has scheduled a conference call for November 13, 2025, at 4:30 p.m. Eastern Time to review the company's third quarter 2025 financial results and provide business updates. The medical technology company will discuss regulatory progress, commercial-readiness activities, and upcoming milestones during the call, which follows the period ended September 30, 2025.
The significance of this announcement extends beyond quarterly financial performance, representing a critical juncture for a company developing technology that could transform cardiac care delivery. HeartBeam is creating the first cable-free device capable of collecting electrocardiogram signals in three dimensions from non-coplanar directions and synthesizing them into a 12-lead ECG. This innovation addresses a fundamental limitation in current cardiac monitoring by enabling comprehensive heart assessment outside clinical settings.
The company's regulatory progress underscores the technology's potential impact on healthcare delivery. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while its 12-Lead ECG synthesis software remains under FDA review. This regulatory pathway indicates the technology's advancement toward clinical implementation and commercial availability.
For patients and healthcare providers, HeartBeam's platform represents a paradigm shift in cardiac monitoring. The technology enables physicians to identify cardiac health trends and acute conditions while directing patients to appropriate care entirely outside medical facilities. This capability could significantly reduce healthcare costs, improve patient convenience, and enable earlier detection of cardiac issues through continuous monitoring in real-world environments.
The company's intellectual property portfolio, comprising over 20 issued patents related to technology enablement, provides competitive protection for its innovations. This extensive patent protection suggests substantial research and development investment and positions HeartBeam as a potential leader in the emerging field of portable cardiac diagnostics. Additional information about the company's developments is available in its newsroom at https://ibn.fm/BEAT.
HeartBeam's upcoming conference call will provide insights into the company's progress toward commercializing technology that could redefine cardiac health management. The ability to deliver actionable heart intelligence through portable devices represents a significant advancement in personalized medicine, potentially enabling more proactive cardiac care and reducing reliance on facility-based monitoring systems that often detect conditions only after symptoms become severe.
